Uncategorized
Cost, prior authorization influences physicians’ treatment preferences for ocular Behçet disease
Rheumatologists and ophthalmologists’ preferences regarding treatment options for ocular Behçet disease are impacted by concerns about cost and prior authorization, according to a study. Of 852 rheumatologists and 934 ophthalmologists who were contacted via email to complete a survey regarding choice of treatment for a patient with ocular Behçet disease, 68 rheumatologists and 64 ophthalmologists completed the survey.